PET-CT

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Retrieved on: 
Wednesday, August 16, 2023
Lymphoma, International Workshop on Lung Health, Waldenström macroglobulinemia, US Foods, University, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, CRS, Fred Hutchinson Cancer Research Center, University of Washington, Clinical trial, Immunoglobulin M, Bone marrow, NHL, PET-CT, Immunotherapy, Associate, Translation, Regenerative medicine, WM, Patient, Cancer, CR, Orphan, Diagnosis, Trial of the century, Hairy cell leukemia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mustang, DSM-IV codes, Food, Safety, Disease, Grade 2, Medical imaging, Vaccine, Pharmaceutical industry

WORCESTER, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”), demonstrating clinical responses as well as safety and efficacy consistent with the ongoing Phase 1/2 clinical trial taking place at Fred Hutchinson Cancer Center (“Fred Hutch”).

Key Points: 
  • The multicenter data also show persistence of CAR-T cells at 6+ months and favorable safety data with only Grade 1 cytokine release syndrome (“CRS”) reported to date.
  • Additionally, the data from the ongoing clinical trial at Fred Hutch continue to demonstrate a high rate of complete and durable responses.”
    Dr. Shadman also presented data from the ongoing Fred Hutch Phase 1/2 clinical trial, specific to two B-NHL cohorts, follicular lymphoma (“FL”) and WM.
  • Furthermore, Mustang anticipates requesting regenerative medicine advanced therapy (RMAT) designation for WM from the FDA in 2024.
  • Finally, data from the Fred Hutch clinical trial also support the potential of MB-106 to be administered as outpatient therapy and provide a best-in-class immunotherapy option for patients treated previously with CD19-directed CAR-T cell therapy.

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

Retrieved on: 
Friday, August 11, 2023
Research, Surgery, Clinical Trials, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Condition, HPP, Neoplasm, Food, Policy, Survival, SCCHN, Head, American Head, PET-CT, Radiation therapy, Congress, NYSE, Patient, Physician, Data, NOCC, FDA, Health Canada, PD-L1, Pembrolizumab, Conference, Pharmaceutical industry, Medical imaging

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.
  • Clinical and Corporate Developments this quarter include:
    CEL-SCI had a productive pre-submission meeting with Canada’s regulator, Health Canada, to determine the best regulatory path toward market approval.
  • CEL-SCI is preparing an application for the NOCC approval as suggested and plans to file it by early next year.
  • CEL-SCI reported a loss per share for the quarter ending June 30, 2023 of $0.19 versus a loss of $0.23 for the quarter of June 30, 2022.

Global Neuroimaging Technology Market 2023: Neuroimaging-as-a-Service for Neuromarketing and Sleep Deprivation Management Presents Opportunities

Retrieved on: 
Tuesday, August 1, 2023
CT, MRF, MPI, Neuroimaging, DSM-IV codes, Network as a service, ZTE, PET-CT, Google Images, MRI, Patient safety, Sleep deprivation, Diagnosis, Neurology, Medical imaging

DUBLIN, Aug. 1, 2023 /PRNewswire/ -- The "Neuroimaging Technology Advances and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 1, 2023 /PRNewswire/ -- The "Neuroimaging Technology Advances and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The neuroimaging industry is dynamic, constantly looking for novel approaches to identify and cure complex neurological disorders.
  • Emerging MRI and CT technologies have helped address the challenges in neuroimaging, such as limited spatiotemporal resolution, cost and accessibility, and patient safety.
  • Finally, this study suggests the growth opportunities in early-stage MRI and CT with the expanding applications of Neuroimaging-as-a-Service (NaaS) in neuromarketing and sleep deprivation management.

Positron Corporation Orders Six Attrius® PET Systems and Components from Neusoft Positron Medical Systems

Retrieved on: 
Monday, July 31, 2023
POSC, Positron Corporation, Positron, PET, Eastman Kodak Co. v. Image Technical Services, Inc., PET-CT, Hospital, Patient, Physician, Molecular imaging, OTC, Growth, Medical imaging

Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company that manufactures, sells and services PET imaging systems and clinical services, is pleased to announce that in combination with its new Business Cooperative Partnership with Shenyang Intelligent Neuclear Medical Technology Co, a wholly owned subsidiary of Neusoft Medical Systems, Positron has agreed on terms to purchase the current inventory from the Company’s PET Joint Venture partner, Neusoft Positron Medical Systems.

Key Points: 
  • Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company that manufactures, sells and services PET imaging systems and clinical services, is pleased to announce that in combination with its new Business Cooperative Partnership with Shenyang Intelligent Neuclear Medical Technology Co, a wholly owned subsidiary of Neusoft Medical Systems, Positron has agreed on terms to purchase the current inventory from the Company’s PET Joint Venture partner, Neusoft Positron Medical Systems.
  • Positron will acquire six (6) Attrius PET systems and all Attrius PET system components held in inventory, with an estimated value of $6 million dollars.
  • The Attrius components inventory provides a full spectrum of parts which will service Attrius PET customers over the next decade.
  • Positron has identified multiple nuclear cardiology practices seeking to purchase Attrius  dedicated PET only systems with several sales proposals currently in the process of acceptance.

Positron Corporation Enters New Manufacturing & Components Supplier Cooperative with Neusoft Medical Systems Subsidiary for New PET-CT Device

Retrieved on: 
Friday, July 21, 2023
Federal Food, Drug, and Cosmetic Act, Communication, POSC, Classification, Positron Corporation, Atakent (business cooperation center), PET-CT, Engineering, Molecular imaging, OTC, Affinity, FDA, LTD, Medical imaging, Positron, Neusoft

Niagara Falls, NY, July 21, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company has entered an Novation Agreement with Shenyang Intelligent Neuclear Medical Technology Co, LTD (Intelligent Neuclear Medical), a wholly owned subsidiary of Neusoft Medical Systems (Neusoft), that transfers the original Business Cooperation Agreement between Positron and Neusoft Medical Systems (“Neusoft”) to now include Neusoft’s subsidiary, Intelligent Neuclear Medical.

Key Points: 
  • Niagara Falls, NY, July 21, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company has entered an Novation Agreement with Shenyang Intelligent Neuclear Medical Technology Co, LTD (Intelligent Neuclear Medical), a wholly owned subsidiary of Neusoft Medical Systems (Neusoft), that transfers the original Business Cooperation Agreement between Positron and Neusoft Medical Systems (“Neusoft”) to now include Neusoft’s subsidiary, Intelligent Neuclear Medical.
  • Positron has expanded its role as manufacturer with Intelligent Neuclear Medical designated as the Company’s contracted components supplier.
  • Positron’s classification as the device manufacturer is significant as it will register with the FDA as the applicant  of its FDA 510k submission for Medical Device Clearance for its Affinity PET-CT imaging device.
  • Neusoft formed Intelligent Neuclear Medical as a wholly owned subsidiary to segregate all Neusoft’s current nuclear projects and products, which also includes all nuclear R&D technology initiatives.

CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer

Retrieved on: 
Friday, July 14, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Condition, Radiation, European Medicines Agency, Policy, Survival, LR, Cancer, SCCHN, Head, Medication, National Comprehensive Cancer Network, SOC, PET-CT, Immunotherapy, Neck, EMA, NCCN, Patient, Standard of care, Risk, Immune system, Diagnosis, Medicines and Healthcare products Regulatory Agency, NOCC, Recurrence, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ITT, NYSE, Food, MHRA, Pharmaceutical industry

During the recent meeting, the FDA acknowledged the longstanding need for improved treatments for head and neck cancer.

Key Points: 
  • During the recent meeting, the FDA acknowledged the longstanding need for improved treatments for head and neck cancer.
  • Preliminary feedback from the FDA included that the selection criteria developed by CEL-SCI could be used to determine which patients should receive Multikine.
  • Based on the feedback received at this recent meeting, CEL-SCI is preparing additional information about its development plan for the next meeting with the agency.
  • These are priority markets for CEL-SCI, as Europe has more than twice the number of head and neck cancer cases diagnosed each year as compared to the U.S.

Global PET Scanners Market Report 2023: Sector is Expected to Reach $1.94 Billion by 2030 at a CAGR of 5.4% - ResearchAndMarkets.com

Retrieved on: 
Monday, May 29, 2023
Medical Devices, Health, Radiation, Prevalence, Noise, TUM, Institute of technology, Cancer, PET, Virtual pet, CVD, Radiopharmaceutical, PET-CT, Bayesian operational modal analysis, Teaching hospital, MRI, Siemens Healthineers, Magnetic resonance imaging, Acquisition, Patient, Chapter Five, Algorithm, PET/CT, Artificial intelligence, Growth, Diagnosis, Digital, AI, Cardiology, Radiation exposure, Prostate cancer, Medical imaging

Digital PET scanners use advanced detectors that can precisely measure the amount of radiation emitted by the tracer.

Key Points: 
  • Digital PET scanners use advanced detectors that can precisely measure the amount of radiation emitted by the tracer.
  • However, as AI technology continues to advance, it is likely to drive the growth of the PET scanners market in the future.
  • The diagnostic imaging centers segment is expected to witness the fastest CAGR of 5.7% over the forecast period.
  • Chapter 5 Pet Scanners Market: Modality Analysis
    Chapter 6 Pet Scanners Market: Application Analysis
    Chapter 7 Pet Scanners Market: End-Use Analysis
    Chapter 8 Pet Scanners Market: Regional Analysis

Micronoma Presents State-of-the-Art Metagenomic Liquid Biopsy Assay for Lung Cancer Detection

Retrieved on: 
Thursday, April 27, 2023
Biotechnology, Health, Genetics, Health Technology, Oncology, Blood, DNA, Cancer, Lung cancer, AACR, Research, PET-CT, Patient, Adenocarcinoma, Carcinoma, AUC, Medical imaging

The recent work adds to the growing body of evidence demonstrating that microbial DNA associated with cancer can be exploited as a novel diagnostic modality.

Key Points: 
  • The recent work adds to the growing body of evidence demonstrating that microbial DNA associated with cancer can be exploited as a novel diagnostic modality.
  • The data presented also demonstrated how the Oncobiota assay, unlike other liquid biopsy assays for lung cancer, uses microbial signals to achieve histological subtype discrimination in lung cancer, providing robust differentiation of lung adenocarcinoma from squamous cell carcinoma (AUC 0.90, discovery cohort, AUC 0.86; blinded validation cohort), information that could aid clinicians in choosing the appropriate therapeutic options.
  • Overall, the presented work found strong diagnostic performance of cell-free metagenomes when evaluating an age-, sex-, and risk-matched and treatment-naive cohort of more than 1,000 patients with lung cancer, benign lung diseases, and no disease (healthy).
  • “These data establish the utility of cell-free metagenomes as a generalizable and sensitive strategy for early lung cancer detection, warranting applications in additional cancer types,” Sepich-Poore noted, pointing towards forthcoming work.

Richter's Syndrome Market Research Report 2023: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecasts, 2017-2022 & 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 26, 2023
Health, Other Health, Lymphoma, Lymphocytosis, Radiation, Prevalence, Chronic lymphocytic leukemia, Epidemiology, Bone marrow, Haematopoietic system, Richter's transformation, PET-CT, Consultant, Aggressive lymphoma, CAR, Patient, Investment, Engineering, Flow cytometry, Diagnosis, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Growth

The "Richter's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Richter's Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The Richter's syndrome market size in top seven countries reached US$ 430.5 Million in 2022.
  • Looking forward, the market in the top seven countries to reach US$ 685.7 Million by 2032, exhibiting a CAGR of 4.32% during 2022-2033.
  • The rising prevalence of aggressive lymphoma in individuals with chronic lymphocytic leukemia and small lymphocytic lymphoma is primarily driving the Richter's syndrome market.

The multimodal Imaging Market is expected to display a steady growth of 5% due to the increasing incidences of chronic disorders | UnivDatos Market Insights

Retrieved on: 
Thursday, February 2, 2023
Carl Zeiss AG, PET/CT, Hospital, Canon Medical Systems Corporation, Disability, SPECT/CT, Midsayap Diagnostic Center and Hospital, Neurology, Oncology, Cardiology, PET/MRI, Research, PET-CT, Alzheimer's disease, Death, Milab, USD, WHO, DSM-IV codes, Disease, GE HealthCare, Growth, Multimodal, Human musculoskeletal system, Conditional sentence, Low back pain, Prevalence, COVID-19, Medical imaging, Cancer, Others, NOIDA

The multimodal imaging market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The multimodal imaging market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities.
  • This innovative report makes use of several analyses to get a closer outlook on the Multimodal Imaging market.
  • The multimodal imaging market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the multimodal imaging market at the global and regional levels.